Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Bourse de Toronto
  5. Sernova Corp.
  6. Summary
    SVA   CA81732W1041

SERNOVA CORP.

(SVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Bourse De Toronto
12/02/2021 12/03/2021 12/06/2021 12/07/2021 12/08/2021 Date
1.32(c) 1.28(c) 1.32(c) 1.32(c) 1.32(c) Last
95 370 132 205 136 000 88 900 66 874 Volume
+2.33% -3.03% +3.13% 0.00% 0.00% Change
More quotes
Estimated financial data (e)
Sales 2021 - - -
Net income 2021 -0,36 M -0,28 M -0,28 M
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Sales 2022 - - -
Net income 2022 -2,29 M -1,81 M -1,81 M
Net Debt 2022 - - -
P/E ratio 2022 -132x
Yield 2022 -
Capitalization 345 M 273 M 272 M
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees -
Free-Float 97,4%
More Financials
Company
Sernova Corp. is a development-stage regenerative medicine company. The Company is engaged in the development of its Cell Pouch and associated technologies, including therapeutic cells for the treatment of chronic diseases and local immune protection technologies. It is focused on developing a treatment for insulin-dependent human diabetes and other metabolic, blood and neurological diseases with therapeutic cells... 
More about the company
All news about SERNOVA CORP.
12/02Sernova Corp. Announces Appointment of Frank Holler as Executive Chair to Complement it..
CI
12/02Sernova Announces Appointment of Executive Chair to Complement its Management Team
AQ
11/16Sernova to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital He..
EQ
11/16Sernova to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital He..
AQ
11/11Sernova Investor Deck November 2021
PU
10/29Sernova Corporate Presentation 2021
PU
10/07SERNOVA : Corporate Presentation October 2021
PU
10/01SERNOVA : The Ultimate Combination of Two Proven Technologies as Potential Functional Cure..
PU
10/01SERNOVA : The Ultimate Combination of Two Proven Technologies as Potential Functional Cure..
AQ
09/29Sernova Corp. Reports Earnings Results for the Third Quarter Ended July 31, 2021
CI
09/29SERNOVA : Engages New York-Based LifeSci Advisors as US Investor Relations Partner
AQ
09/16Sernova Corp. Signs Collaboration Agreement to Advance Conformal Coated Immune Protecte..
CI
09/16SERNOVA : Signs Collaboration Agreement to Advance Conformal Coated Immune Protected Thera..
AQ
08/09SERNOVA : to Present Corporate Update at Canaccord Genuity's 41st Annual Growth Conference
AQ
07/05SERNOVA ANNOUNCES 2021 ANNUAL MEETIN : Shareholders Approve Resolutions with Overwhelming ..
PU
More news
News in other languages on SERNOVA CORP.
12/02SERNOVA CORP. : Sernova gibt Ernennung von Executive Chair zur Unterstützung des Managemen..
11/16Sernova präsentiert beim Canaccord Genuity Virtual MedTech, Diagnostics and Digital Hea..
11/16Sernova präsentiert beim Canaccord Genuity Virtual MedTech, Diagnostics and Digital Hea..
10/01SERNOVA CORP. : Sernova: Die ultimative Kombination zweier bewährter Technologien als pote..
09/29SERNOVA CORP. : Sernova beauftragt die New Yorker Firma LifeSci Advisors als Investor Rela..
More news
Chart SERNOVA CORP.
Duration : Period :
Sernova Corp. Technical Analysis Chart | SVA | CA81732W1041 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,32 CAD
Average target price 2,50 CAD
Spread / Average Target 89,4%
EPS Revisions
Managers and Directors
Philip M. Toleikis President, Chief Executive Officer & Director
David Swetlow Chief Financial Officer
Frank A. Holler Chairman
Delfina Siroen Senior Director-Research & Development
Jeffrey A. Bacha Independent Director
Sector and Competitors